NDAORALCAPSULE
Approved
May 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ZEMPLAR (paricalcitol) by AbbVie is synthetic, biologically active vitamin d 2 analog. Approved for secondary hyperparathyroidism, chronic kidney disease, hemodialysis. First approved in 2005.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZEMPLAR (paricalcitol) is a synthetic vitamin D2 analog that selectively activates vitamin D receptor pathways to reduce PTH synthesis and secretion. It is indicated for secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis. The drug works by binding to the vitamin D receptor and modulating calcium-phosphorus metabolism in the renal patient population.
LOE Approaching
ZEMPLAR is in late-stage lifecycle with approaching loss of exclusivity, signaling potential team consolidation and transition focus toward managed decline or generic co-promotion strategies.
Mechanism of Action
synthetic, biologically active vitamin D 2 analog. Preclinical and in vitro studies have demonstrated that paricalcitol's biological actions are mediated through binding of the vitamin D receptor (VDR), which results in the selective activation of vitamin D responsive pathways. Vitamin D and…
Pharmacologic Class:
Vitamin D2 Analog
Indications (3)
Worked on ZEMPLAR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.